Enrollment is Open: Participants Needed
Sponsored by The National Institute of Allergy and Infectious Disease and The Immune Tolerance Network
A randomized, multicenter trial for patients with severe ANCA-associated vasculitis.
Participants will be randomized to either a treatment of cyclophosphamide (CYC) and prednisone or rituximab and prednisone.
The primary objective of this trial is to determine the efficacy of rituximab and glucocorticoids in the induction of remission of ANCA-associated vasculitis.
For further detailed information: http://vasculitis.med.jhu.edu
Study Coordinators:
Lourdes Sejismundo (410) 550-6818 or
Yavette Goldsborough (410) 550-4580
Email: jhvc@jhmi.edu
Lead Investigators:
Ulrich Specks, M.D.,
Division of Pulmonary and Critical Care, Mayo Clinic
Co-directors: Philip Seo, M.D./Stuart Levine, M.D.,
The Johns Hopkins Vasculitis Center
Participating Medical Centers
Boston University
Cleveland Clinic
Duke University
Hospital for Special Surgery, New York City
Mayo Clinic
The Johns Hopkins Vasculitis Center
University of Alabama at Birmingham